Why the study?
Does matrix metalloproteinase 2 (MMP-2) expression predict survival in patients with non-small cell lung cancer?
Does matrix metalloproteinase 2 (MMP-2) expression predict survival in patients with non-small cell lung cancer?
MMP-2 expression is associated with worse survival in patients with non-small cell lung cancer, suggesting its potential utility as a prognostic biomarker.
May support MMP-2 as prognostic biomarker in NSCLC; leaves open need for prospective validation before clinical adoption.
To evaluate the prognostic value of matrix metalloproteinase2 (MMP-2) expression in patients with non-small cell lung cancer (NSCLC), the electronic database PubMed, EMBASE were searched for relevant articles. The meta-analysis was finally based on 11 studies that included 1,439 patients, and combined HR was 1.66 (95% confidence intervals (CI: 1.37-2.01). Its effect also appeared significant when the analysis was restricted to tumor cell expression and patients with adenocarcinoma (HR 2.08 (95% CI: 1.24-3.48)). This study supported the fact that MMP-2 could be included in further prospective trials studying prognostic factors in NSCLC.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: